Report: DNA-based injections to fuel growth of animal vaccines market

U.K.-based Companies and Markets, an aggregator of market research, has released a report predicting the global market for animal vaccines will hit $7.2 billion by 2020--driven largely by DNA-based products. These vaccines stimulate the immune system not with the infectious agent itself, but rather with DNA encoding the antigens that prompt the desired immune response. DNA vaccines could offer many advantages, including improved stability and the ability to quickly scale up manufacturing. Several DNA vaccines are already on the market in animal health, including a product to prevent West Nile virus in horses. The report predicts that demand in both human and animal health will drive total sales of DNA-based vaccines from $305 million a year in 2014 to $2.7 billion by 2020. Article

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…